

Current report 4/2021
January 18, 2021

Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR

Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow ("Company") hereby announces that on January 18, 2021 its Project titled "Clinical development of an innovative drug candidate in solid tumors" ("Project") has been approved for financing by the National Center for Research and Development (NCBiR) within the Smart Growth Operational Programme 2014-2020, measure 1.1.1. "Fast Track".

The goal of the project is to implement into Ryvu Therapeutics S.A. business portfolio a new drug candidate – inhibitor of CDK8/19 kinases, evaluated in phase I/II of clinical study (until stage of dose expansion) in patients with solid tumors. The compound should overcome limitations of current treatment options, benefitting patients with most aggressive solid tumors who have exhausted currently available therapeutic options.

- Project net value: PLN 42 696 464;
- Recommended grant financing: PLN 18 939 762.79 which is the total amount of grant financing requested by the Company;
- Project timelines: September 2020 - December 2023.

The final grant financing may be slightly changed at the stage of preparing the documentation for the final grant agreement. The Company will inform about its conclusion in a separate current report.

Legal basis: Article 17.1 of the Market Abuse Regulation

Representatives of the Company:

- Setareh Shamsili – Vice President of the Management Board
- Tomasz Nocuń – Proxy